Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Collegium Pharmaceutical reported revenue of $205.45 million for the quarter ended December 2025, reflecting a year-over-year increase of 12.9% [1] - The earnings per share (EPS) for the quarter was $2.04, up from $1.77 in the same quarter last year, but below the consensus estimate of $2.19, resulting in an EPS surprise of -6.99% [1] - The revenue fell short of the Zacks Consensus Estimate of $208.65 million, leading to a revenue surprise of -1.53% [1] Revenue Breakdown - Total product revenues for Belbuca reached $59.14 million, exceeding the three-analyst average estimate of $58.03 million, with a year-over-year change of +7.1% [4] - Xtampza ER generated $48.58 million in product revenues, which was below the average estimate of $51.37 million, showing a year-over-year decline of -5.6% [4] - Symproic reported revenues of $3.89 million, surpassing the average estimate of $3.53 million, but reflecting a year-over-year decrease of -8.6% [4] - Nucynta achieved $47.95 million in revenues, slightly below the average estimate of $49.47 million, with a year-over-year increase of +14.8% [4] - Jornay PM's revenues were $45.89 million, close to the average estimate of $46.46 million [4] Stock Performance - Collegium Pharmaceutical's shares have returned +2.1% over the past month, outperforming the Zacks S&P 500 composite, which changed by +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]